Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Structures of influenza A proteins and insights into antiviral drug targets.

Das K, Aramini JM, Ma LC, Krug RM, Arnold E.

Nat Struct Mol Biol. 2010 May;17(5):530-8. doi: 10.1038/nsmb.1779. Epub 2010 Apr 11. Review.

2.

A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.

Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, Kundi M, Popow-Kraupp T, Redlberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, Bergmann M, Romanova J, Roethl E, Morokutti A, Wolschek M, Ferko B, Seipelt J, Dick-Gudenus R, Muster T.

J Infect Dis. 2010 Feb 1;201(3):354-62. doi: 10.1086/649428.

PMID:
20039806
3.

Immunization with live attenuated influenza viruses that express altered NS1 proteins results in potent and protective memory CD8+ T-cell responses.

Mueller SN, Langley WA, Carnero E, García-Sastre A, Ahmed R.

J Virol. 2010 Feb;84(4):1847-55. doi: 10.1128/JVI.01317-09. Epub 2009 Nov 25.

4.

Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009.

Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Sugerman DE, Druckenmiller JK, Ritger KA, Chugh R, Jasuja S, Deutscher M, Chen S, Walker JD, Duchin JS, Lett S, Soliva S, Wells EV, Swerdlow D, Uyeki TM, Fiore AE, Olsen SJ, Fry AM, Bridges CB, Finelli L; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team.

N Engl J Med. 2009 Nov 12;361(20):1935-44. doi: 10.1056/NEJMoa0906695. Epub 2009 Oct 8.

5.

Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Romanova J, Krenn BM, Wolschek M, Ferko B, Romanovskaja-Romanko E, Morokutti A, Shurygina AP, Nakowitsch S, Ruthsatz T, Kiefmann B, König U, Bergmann M, Sachet M, Balasingam S, Mann A, Oxford J, Slais M, Kiselev O, Muster T, Egorov A.

PLoS One. 2009 Jun 19;4(6):e5984. doi: 10.1371/journal.pone.0005984.

6.

Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.

Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, López-Gatell H, Olivera H, López I, Myers CA, Faix D, Blair PJ, Yu C, Keene KM, Dotson PD Jr, Boxrud D, Sambol AR, Abid SH, St George K, Bannerman T, Moore AL, Stringer DJ, Blevins P, Demmler-Harrison GJ, Ginsberg M, Kriner P, Waterman S, Smole S, Guevara HF, Belongia EA, Clark PA, Beatrice ST, Donis R, Katz J, Finelli L, Bridges CB, Shaw M, Jernigan DB, Uyeki TM, Smith DJ, Klimov AI, Cox NJ.

Science. 2009 Jul 10;325(5937):197-201. doi: 10.1126/science.1176225. Epub 2009 May 22.

7.

Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I.

Gack MU, Albrecht RA, Urano T, Inn KS, Huang IC, Carnero E, Farzan M, Inoue S, Jung JU, García-Sastre A.

Cell Host Microbe. 2009 May 8;5(5):439-49. doi: 10.1016/j.chom.2009.04.006.

8.

Influenza A virus TRIMs the type I interferon response.

Ludwig S, Wolff T.

Cell Host Microbe. 2009 May 8;5(5):420-1. doi: 10.1016/j.chom.2009.05.004.

9.

Emerging antiviral targets for influenza A virus.

Krug RM, Aramini JM.

Trends Pharmacol Sci. 2009 Jun;30(6):269-77. doi: 10.1016/j.tips.2009.03.002. Epub 2009 May 8. Review.

10.

Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate.

Wressnigg N, Voss D, Wolff T, Romanova J, Ruthsatz T, Mayerhofer I, Reiter M, Nakowitsch S, Humer J, Morokutti A, Muster T, Egorov A, Kittel C.

Vaccine. 2009 May 11;27(21):2851-7. doi: 10.1016/j.vaccine.2009.02.087. Epub 2009 Mar 11.

PMID:
19366569
11.

Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses.

Chambers TM, Quinlivan M, Sturgill T, Cullinane A, Horohov DW, Zamarin D, Arkins S, García-Sastre A, Palese P.

Equine Vet J. 2009 Jan;41(1):87-92.

12.

Pandemic influenza: an inconvenient mutation.

Layne SP, Monto AS, Taubenberger JK.

Science. 2009 Mar 20;323(5921):1560-1. doi: 10.1126/science.323.5921.1560. No abstract available.

13.

Influenza B mutant viruses with truncated NS1 proteins grow efficiently in Vero cells and are immunogenic in mice.

Wressnigg N, Shurygina AP, Wolff T, Redlberger-Fritz M, Popow-Kraupp T, Muster T, Egorov A, Kittel C.

J Gen Virol. 2009 Feb;90(Pt 2):366-74. doi: 10.1099/vir.0.006122-0.

PMID:
19141445
14.

Novel influenza virus NS1 antagonists block replication and restore innate immune function.

Basu D, Walkiewicz MP, Frieman M, Baric RS, Auble DT, Engel DA.

J Virol. 2009 Feb;83(4):1881-91. doi: 10.1128/JVI.01805-08. Epub 2008 Dec 3.

15.

Influenza a virus polymerase is an integral component of the CPSF30-NS1A protein complex in infected cells.

Kuo RL, Krug RM.

J Virol. 2009 Feb;83(4):1611-6. doi: 10.1128/JVI.01491-08. Epub 2008 Dec 3.

16.

Adjuvant activity of type I interferons.

Tovey MG, Lallemand C, Thyphronitis G.

Biol Chem. 2008 May;389(5):541-5. Review.

PMID:
18953720
17.

The multifunctional NS1 protein of influenza A viruses.

Hale BG, Randall RE, Ortín J, Jackson D.

J Gen Virol. 2008 Oct;89(Pt 10):2359-76. doi: 10.1099/vir.0.2008/004606-0. Review.

PMID:
18796704
18.

Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.

Hai R, Martínez-Sobrido L, Fraser KA, Ayllon J, García-Sastre A, Palese P.

J Virol. 2008 Nov;82(21):10580-90. doi: 10.1128/JVI.01213-08. Epub 2008 Sep 3.

19.

Progress in identifying virulence determinants of the 1918 H1N1 and the Southeast Asian H5N1 influenza A viruses.

Basler CF, Aguilar PV.

Antiviral Res. 2008 Sep;79(3):166-78. doi: 10.1016/j.antiviral.2008.04.006. Epub 2008 May 23. Review.

20.

Emerging viral diseases.

Pekosz A, Glass GE.

Md Med. 2008 Winter;9(1):11, 13-6. Review. No abstract available.

Supplemental Content

Support Center